Summit signs deal with Eurofarma for Latin American rights to Ridinilazole
Summit retains commercialisation rights in all other countries. Ridinilazole is a targeted antibiotic that has the potential as a frontline therapy to treat initial infection and preserve patients'
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.